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CHAPTER I 
INTRODUCTION 
The number one cause of death in the United States 
today is cardiovascular disease (CVD). This disease claims 
more than 500,000 lives annually, and is debilitating to 
another 500,000 (45). In addition to the many lives lost to 
atherosclerosis, it should be noted that a great deal of 
money and productive work time are lost to the disease as 
well. It is estimated that the cost of heart disease alone 
is equal to one-fifth of the Gross National Product (45). 
Many risk factors have been associated with the 
development of atherosclerosis. Risk factors are 
categorized as non-modifiable and modifiable (15). Non-
modifiable risk factors, those that can not be significantly 
altered through lifestyle changes, are; (1) genetic 
predisposition towards the disease, (2) age, and (3) gender. 
Risk factors that are modifiable through lifestyle changes 
are; (1) smoking, (2) stress, (3) maintaining ideal body 
weight, and (4) exercise. Two additional risk factors which 
play an important role in the propensity for developing 
coronary heart disease (CHD), which can be included in both 
categories, are hypertension and increased cholesterol 
levels in the blood. These are affected by lifestyle, but 
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can be dependent on genetic predisposition as well. 
Physicians and health care professionals have long 
advocated that the fat content in the diet be decreased 
(29). Diets high in fat are a part of the American way of 
life. It is estimated that in the average diet 40% of the 
total kilocalories are derived from fat, 30% from 
carbohydrates, and 30% from protein (54). In contrast, the 
American Heart Association has recommended that these levels 
be changed to 30-58-12, respectively (1). For those 
patients that have already developed atherosclerotic lesions 
the recommendation is even lower, 20% total fat. It is easy 
to see why Americans gain an average of a pound to a pound 
and a half a year from the ages of 20 to 40. Fat contains 9 
kcal. per gram while carbohydrates and proteins contain 4.5 
kcal. per gram (8). 
Consuming a diet high in fat, and particularly high in 
saturated fat, activates the body's mechanism to produce 
cholesterol (1,54). These high levels of cholesterol in the 
blood (hypercholesterolemia) cause the build up of 
atherosclerotic plaque in the intima of arteries, primarily 
in the heart, brain, and peripheral vessels (54). This 
build up continues over a period of time until the vessel 
becomes completely occluded, usually as a result of thrombus 
formation. When this occurs, distal blood flow from the 
lesion is compromised, and an infarction can occur. There 
is increased emphasis on the causal connection between 
hyperlipidemia and the development of CHD (22,26,29,41). 
Although the clinical range of values for total cholesterol 
is from 100-300 mg./dl., the Center for Disease Control, as 
well as the Lipid Research Clinics Coronary Primary 
Prevention Trial (LRC-CPPT) and the National Heart Lung and 
Blood Institutes (NHLB) are now recommending that values do 
not exceed 200 mg./dl. for those over 40 years of age, and 
180 mg./dl. for those under age 40 (2,39). Perhaps even 
more important in the prevention of CHD is the measurement 
of the levels of lipoproteins, the cholesterol-carrying 
molecules in the blood. Some authors consider these 
lipoproteins a more accurate predictor for the development 
of atherosclerosis than total cholesterol alone (10,11,26). 
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Given that there is a definite causal connection 
between the development of hyperlipidemia and CHD, how can 
this disorder be reversed? At the outset it is essential to 
accurately measure blood cholesterol levels in the general 
population. After individuals with adverse blood lipids are 
identified, there should be specific and uniform 
recommendations made on how to reduce these elevated 
levels ( 2) . 
The current thought is to initially recommend a diet 
low in fat (30%) and particularly low in saturated fat, with 
no more than a two to one ratio of polyunsaturated to 
saturated fat advocated (45). After having followed this 
stringent dietary regimen for a period of 3 months the 
hyperlipidemic patient should be retested. If the condition 
persists, the physician may choose to place the patient on 
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anti-hyperlipidemic drug therapy (22). 
Although the above treatments are widely recognized as 
acceptable medical practice, a third alternative is 
possible. Many studies have demonstrated that decreased 
blood cholesterol levels can be achieved by supplementing 
the regular diet with increased amounts of eicosapentanoic 
acid (EPA) (28,36,37,40,42). This observation was first 
made among Greenlandic Eskimos who ingest a diet similar to 
those of carnivorous mammals, i.e., very little carbohydrate 
and high fat and protein. Despite the fact that this 
dietary regimen is contrary to the current recommendation, 
very low cholesterol levels and a low incidence of coronary 
heart disease are reported for this group (4-6,17-20). 
This evidence strongly supports the idea that a third 
treatment may be possible. For instance, if supplementing 
the normal diet with fish oil (marine lipids having a high 
concentration of EPA and DHA, omega-3 fatty acids) produces 
the desired effects of lowering cholesterol levels, it may 
be possible to not only decrease cholesterol levels, but 
also to do so in a manner that is not disruptive to the 
individual's normal living patterns. 
Additional research is warranted in this area as 
specific mechanisms of action, dosage levels, as well as 
over-all effectiveness in different populations are not 
clearly understood. Therefore, this investigation is 
intended to critically evaluate the effect of MaxEPA (tm) (a 
commercially prepared fish oil) on serum cholesterol, high 
density lipoprotein cholesterol, and bleeding time in 
patients with a history of coronary heart disease. If the 
results of the investigation support the hypothesis that 
fish oils are beneficial, then it can be concluded that a 
low cost means for controlling lipid levels and thereby 
decreasing the incidence of CHD will have been found. 
Statement of the Problem 
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This study investigated the effect of MaxEPA (tm) on 
serum cholesterol, high density lipoprotein cholesterol, and 
bleeding time in adult patients with hyperlipidemia and 
coronary heart disease. 
Hypotheses 
1. There will be no significant change in the total serum 
cholesterol level after dietary supplementation of 10 MaxEPA 
(tm) capsules (1.8 g.EPA) daily for a three week period. 
2. There will be no significant change in high density 
lipoprotein cholesterol (HDL/C) after dietary 
supplementation of 10 MaxEPA (tm) capsules (1.8 g.EPA) daily 
for a three week period. 
3. There will be no significant change in bleeding time 
after dietary supplementation of 10 MaxEPA (tm) capsules 
(1.8 g.EPA) daily for a three week period. 
Limitations of the Study 
1. All subjects were volunteers with documented histories 
of coronary artery disease. 
2. No medications (including aspirin) were discontinued 
during testing. 
3. The placebo used was an olive oil based placebo in 
capsule form furnished by the R. P. Shearer Co. 
Delimitations of the Study 
1. The subjects were limited to 9 males and 2 females 
chosen from a group of patients that had undergone cardiac 
rehabilitation at the Oklahoma State University Health and 
Fitness Center. 
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2. All subjects were hypercholesterolemic, i.e., had total 
serum cholesterol levels of 200 mg./dl. or above, or a total 
cholesterol to high density lipoprotein-cholesterol of 5:1 
or greater. 
3. Total serum cholesterol levels were measured using the 
Vision (tm) automated blood analyzer manufactured by Abbott 
Laboratories. 
4. HDL/cholesterol was measured via the Sigma enzymatic 
reaction method and measured in the Vision {tm) automated 
blood analyzer. 
6. Bleeding time was measured via Duke's method. A uniform 
puncture depth was accomplished by using the Autolet (tm) 
lancet. 
Assumptions 
1. High density lipoprotein cholesterol (HDL/C) being 
considered "good" cholesterol, the remainder of total not 
being HDL/C is then, LDL/C, and VLDL/C, or "bad" 
cholesterol. 
2. It is assumed that the protocol for ingestion of 
capsules, as well as adherence to dietary and exercise 
regimes, was maintained. 
Definition of Terms 
Conceptual 
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Arachidonic~ (AA). (eicosatetraenoic acid, C20:4w-
6) Used in the vessel wall and by platelets, the precurser 
to thromboxane A2 and prostaglandin I2. (4) 
Atherosclerosis. A form of arteriosclerosis in which 
there are localized accumulations of lipid containing 
material (atheromas) within or beneath the intimal layer of 
blood vessels. (54) 
Atherosclerotic Heart Disease. Atherosclerosis 
affecting the coronary arteries. 
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At~~scle£QtiQ ~~iQrr. An area of pathologically 
injured tissue due to the build up of cholesterol placque in 
the intima of a vessel. 
Bleeding Tim~. The time required for blood to stop 
flowing from a small wound. Normal bleeding time using 
Duke's method is 1-3 minutes. (56) 
Qgrbohydrgt~. Foods containing only carbon combined 
with hydrogen and oxygen, in the ratio of two hydrogens for 
each carbon and oxygen, such as sugars, starch, and 
cellulose. (56) 
QQ£Qrrary Artery Diseas~. Atherosclerotic lesions 
affecting one or more of the coronary arteries. (57) 
Q~1Qy~ular lli~~ (CVD). All diseases affecting 
the cardiovascular system including coronary heart disease, 
atherosclerosis, high blood pressure, stroke, rheumatic 
fever, rheumatic heart disease. (57) 
Cholesterol (C27H450H). A sterol widely distributed in 
animal tissues and occurring in the yolk of eggs, various 
oils, fats, and nerve tissue. (54, 57) 
HO 
Chylomicron. The largest and lightest lipoproteins 
consisting of 80-90% exogenous triglyceride, 2-7% 
cholesterol, 3-6% phospholipid, and 1-2% protein. They are 
normally synthesized in the intestine and transport dietary 
triglyceride from there into the plasma. (54) 
Docosahexaenoic AQld (DHA). (C22:6) An Omega-3 fatty 
acid the with first double bond 3 carbons away from the 
terminal CH3. ( 4-6) 
HOOC 
Eic~entanoic AQ!d iKfAl. (C20:5) An Omega-3 fatty 
acid with the first double bond 3 carbons away from the 
terminal CH3. The major constituent in fish oil and 
considered the active structure. (4-6) 
ErYthrocyte. A red blood cell. (57) 
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EsterifiQation. An organic reaction between an alcohol 
and an organic acid, such as when a fatty acid reacts with a 
cholesterol molecule. (55) 
[at. Triglyceride ester of fatty acids. The term 
lipid is applied in general to a fat or fatlike substance. 
Fats are insoluble in water. (54,57). 
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fatty AQiQ. Usually found in natural triglygerides in 
foods and in human lipids and consisting of an even number 
of carbon atoms arranged in a straight chain-with a carboxyl 
group at one end. They may be saturated or 
unsaturated. (54) 
COOH 
~~nYlQQYt~- A granular leukocyte. A 
polymorphonuclear leukocyte (neutrophil, eosinophil, or 
basophil). (57) 
Herterozygoua. Having unlike genes. In familial 
hypercholesterolemia having one affected gene. (57) 
tl1gh Density Lipoprotein CholesterQl (HDL/C). The 
smallest of the lipoproteins, contains approximately 45-50% 
protein, 30% phospholipid, and 20% cholesterol and is a 
normal component of fasting plasma. The so-called "good 
cholesterol" due to its ability to act as an atherosclerotic 
placque scavenger in the circulatory system. (54) 
Homozygous. Produced by similar gametes (a mature 
reproductive cell). In familial hypercholesterolemia having 
affected genes from both parents. (57) 
Linoleic~- (C:18w6) A long chain fatty acid with 
the first double bond occurring nine carbons from the 
terminal COOH. The primary constituent of polyunsaturated 
vegetable oil. (36) 
CH3 COOH 
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kiQids. Any one of a group of fats or fatlike 
substances, characterized by their insolubility in water. 
Most often, somewhere in the molecular structure of lipids 
is a fatty acid or a fatty acid derivative. Lipids include 
triglycerides, phospholipids, sterols and sterol esters, 
glycolipids and lipoproteins. (54, 57) 
Lipoprotein. The carrier protein for lipids. The 
cholesterol lipoproteins are, HDL, LDL, VLDL, and 
chylmicrons. (57) 
Low Den~ Lipoprotein (LDL). Partially or completely 
resulting from the metabolism of VLDL. It is about 50% 
cholesterol and 25% protein by weight and normally carries 
one half to two thirds of the total plasma cholesterol. The 
so-called "bad cholesterol" because of its greater 
athrogenic potential. LDL is slowly removed by the liver 
(2-5 days) and is what is mostly measured in a total 
cholesterol blood test. (57) 
Lymphocyte. White blood cell without cytoplasmic 
granules. Normally 20-50% of the white cells. (57) 
MaxEPA (tm). A commercially prepared food supplement 
of triglyceride marine lipids containing EPA (180 mg./gram 
capsule), DHA (120 mg./gram capsule), < 1 gram protein, < 1 
gram carbohydrate, 15 mg. cholesterol, and 7 % 
vitamin E. 
Monocyte. A large mononuclear leukocyte having more 
protoplasm than a lymphocyte. (57) 
Monosaturated ~~(oleic acid). (C18:1,w-9) Having 
the maximum number of hydrogen atoms attached to only one 
carbon. A example of a monosaturated fat that is rich in 
oleic acid is commonly known as olive oil. (28) 
COOH 
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Omeg~ fattx scid (w-3 FA). A class of fatty acids so 
named because the first double bond is located 3 carbon 
atoms away from'the terminal CH3. (4) 
~(prostaglandin I2). A prostacyclin synthesized 
in the vessel wall from arachidonic acid having anti-
aggregating effects on platelets. (4) 
PGI3 (prostaglandin I3). A prostacyclin synthesized in 
the vessel wall from eicosapentanoic acid having anti-
aggregating effects on platelets. (4) 
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Phospholipids. Usually derived from a glycerol. They 
contain two fatty acids, at least one of which is 
unsaturated, phosphate and a nitrogen base, most frequently 
choline. Since triglycerides are fat soluble and enzymes 
are water soluble, in order for enzyme-substrate 
interaction to take place, neutral fats (triglycerides) must 
be emulsified. Phospholipids in tissue and foods can act as 
emulsifying agents which aid in digestion of fats. (54) 
0 
0 
II 
C-0-C-R 
I II 
R-C-0-C-H 
0 
II 
C-0-P-O-CH2-CH2-N-(CH3) 
I 
0 
(Lecithin, a phospholipid) 
Plasma. The liquid portion of blood. (57) 
Platelet. A round or oval disk found in blood. 
Important in blood coagulation, hemostasis, and blood 
thrombus formation. (57) 
Platelet AggregatlQn. The ability of platelets to form 
clusters or stick to each other. (57) 
Prostaglandins. A group of fatty acid derivatives 
present in many tissues. There are more than a dozen 
prostaglandins. They are extremely active biological 
substances which affect the cardiovascular system, smooth 
muscle, and stimulate the uterus to contract. (54) 
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QgtUrgt~~ [at (fatty acid). (Cn H2n 02) A fat that is 
a solid at room temperature. Except for the terminal 
carboxyl group, both available bonds for each carbon in the 
chain are occupied by hydrogens. (8) 
H H H 0 
I I I 'i' 
R-e-e-c-e 
I I I ' H H H OH 
Q§~um. The watery portion of blood remaining after a 
clot has formed. (57) 
Thromboxa~ A2 (TxA2). Derived by platelets from 
arachidonic acid. A pro-aggregating agent. (4) 
Ihromboxane A3 (TxA3). Derived by platelets from 
eicosapentanoic acid. Has no aggregating properties. (4) 
Thromboxane B2 (TxB2). A metabolite of TxA2 and 
excreted in the urine. (50) 
Ih~mbQxg~ ~ (TxB3). A metabolite of TxB3 and 
excreted in the urine. (50) 
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TriglyQ~rid~. Also called neutral ~ats, are fatty acid 
esters of glycerol. The physical state of the triglycerides 
depends on the chain length and degree of unsaturation of 
their fatty acid components-the more unsaturated the fatty 
acids and the shorter the chain length, the lower the 
melting point of the fat. A component of lipoproteins and 
highly associated with VLDL. (57) 
0 
II 
H-C-0-C-R----fatty 
"I 0 
II 
acid 1 
H-C-0-C-R----fatty acid 2 
0 
II 
HZC-0-C-R----fatty acid 3 
Unsaturated Fat (fatty acids). A liquid at room 
temperature. One hydrogen atom is missing from each of two 
adjacent carbons, which then share a double bond. (8) 
H H H H 
I I I I 
R-C-C=C-C-R 
j I 
H H 
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Y.§.IT LoH. Density Lipoprotein (VLDL). The second 
lightest lipoprotein next to the chylomicrons. They are 
glyceride-rich (60-80%). They carry endogenous 
triglycerides (which appear to originate predominantly in 
the liver) from the liver to peripheral sites in muscle and 
adipose tissue. Once in the plasma, VLDL are quickly 
attacked by the same lipases that act on chylomicrons and in 
a few hours become an intermediate lipoprotein form divested 
of much triglyceride and some protein. Within 2-6 hours it 
is further depleted of triglyceride and becomes LDL. (54) 
Xanthomg_. A slightly elevated, soft rounded placque or 
nodule, usually on the eyelids. A characteristic finding in 
familial hypercholesterolemia. (54) 
Hypercholesterolemic Q~Qiect. A subject having a total 
cholesterol greater than 200 mg./dl. 
~i§.Qt. with QQ.I:.Qnru:Y. tl§.art D.i§.§.g_se. A subject that 
has experienced a myocardial infarcton, coronary artery 
bypass graft surgery, or coronary balloon angiography. 
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Description of Instruments 
Vision itm) AlltQmated alQod AnalY~- An instrument 
used to measure different components of the blood. A self 
contained wet-chemistry blood analyzer. This instrument is 
fully automated. 
Spring Agtuated k~ncet. A lancet attached to a 
mechanical device that punctures the skin to a uniform 
depth. 
lEC Clinical Centrifuge. A variable speed (1,500 to 
2,000 revolutions per minute), table top centrifuge. 
CHAPTER II 
A SELECTED REVIEW OF LITERATURE 
As early as 1971 Bang and Dreyerberg noted that 
Greenlandic Eskimos had a low rate of mortality from 
coronary heart disease (4). They tested the blood of 130 
Eskimos for total cholesterol, triglycerides, phospholipids, 
and lipoproteins (VLDL, LDL, HDL, and chylomicrons) and the 
results were compared to a control group comprised of 
healthy Danes and Eskimos living in Denmark. Greenlandic 
Eskimos were found to have a much lower level of pre-beta-
lipoprotein (VLDL), and consequently a lower triglyceride 
level. The fact that low mortality rates for the 
Greenlandic Eskimos correlated with low triglyceride levels 
coincided with the idea prevalent at the time that high 
triglyceride levels were thought to have a direct causal 
effect on the development of CHD (32). 
In 1978 Bang and Dryerberg reported the results of 
another study conducted on similar populations in which a 
correlation was found to exist between the lower incidence 
of coronary events for Greenlandic Eskimos and increased 
bleeding times (4). It was believed that this finding might 
have a bearing on the frequency of CHD development which 
they sought to explain. 
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From the first study the Eskimo diet was determined to 
be very high in fat (280 gm./day) and protein (135 gm./day), 
low in carbohydrates, since their primary food was fish. 
Ironically, this was not consistent with what was known 
about diet and coronary heart disease, however, it was 
hypothesized that diet was probably the key consideration. 
It should be noted that neither genetic predisposition, nor 
exercise were regarded at this point in their 
investigations. Additionally, they alluded to a possible 
role for the recently discovered compounds called 
prostaglandins which appeared to have many functions within 
the human body (4). 
Prostaglandins are hormone like compounds, synthesized 
in various tissues from arachidonic acid (C20:4w-6) (AA). 
Among their many functions they are known to regulate 
reactions in the inhibition of gastric secretion, decrease 
blood pressure, and interact with other hormones (6). Bang 
and Dryerberg thought that these new compounds might contain 
the key to confirming a causal relationship between the 
lower lipids levels, longer bleeding times, and decreased 
CHD mortality (4). 
Bang and Dryerberg found that one of the major 
components of the fish in the Eskimo diet was 
eicosapentanoic acid (C20:5w-3) (EPA), an omega-3 
polyunsaturated fatty acid, which they proposed successfully 
decreases platelet aggregation and thereby increases 
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bleeding times (5,6). In order to do this, EPA (present in 
quantity) must compete against arachidonic acid in its 
reactions to produce thromboxane A2 (TxA2), a pro 
aggregating substance that also causes vasoconstriction. 
EPA, using the same enzyme, cyclooxygenase, used by AA, 
reacts to produce the biologically inert thromboxane A3 
(TxA3). Both thromboxanes in further reactions produce 
prostacyclins PGI2 and PGI3 respectively, both of which are 
vasodilators and platelet aggregation inhibitors. So the 
one step of value in the EPA reactions is the elimination of 
TxA2 the vasoconstrictor and platelet aggregator, therefore 
increasing bleeding times (4). 
Bang and Dryerberg proceeded then to measure the 
percentage of total fatty acids in the lipid fractions of 
blood in the Eskimos and Danes (4). Greater percentages of 
EPA were indeed found in the Eskimo lipids than in the Danes 
as well as lower plasma cholesterol and triglyceride 
levels. These findings were so significant that a separate 
study based upon the same arguments was reported in the 1979 
Lancet (5). 
Investigations into the effects of fish-oil continued 
through the early 1980's (24,35,50,58). Recognition was 
eventually given to the work by the Editorial board of the 
~ ~ England Journal Qi Medicine, when a section of three 
articles devoted to the promotion of the hypothesis that an 
increase in dietary fish consumption could decrease the 
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incidence of CHD appeared in the May 1985 issue (40,42,46). 
In one of these, a study of the inverse relationship of 
mortality from CHD in those that consumed fish over those 
that did not, left little doubt a diet high in marine lipids 
could decrease the number of deaths attributable to CHD 
(42). The two remaining articles addressed the problems 
associated with the identification of the process or 
processes by which fish oil affected the metabolism. 
Results from the work of Phillipson et al. (46) favored the 
changes that marine lipids had on triglyceride metabolism, 
while Lee et al. (40), suggested that a diet containing 
fish-oil polyunsaturated fatty acids altered the function of 
monocytes and their interaction with the endothelium. 
It was clearly the empirical view of these authors that 
an increased dietary consumption of fish-oil (EPA) would 
decrease the incidence of CHD by decreasing cholesterol and 
triglyceride levels, increasing HDL, and increasing bleeding 
time (23). It was also evident that more research was 
needed in order to fully understand what mechanism was 
involved and what dosage regimen was needed to produce the 
desired effects. 
At this point in time, there is little doubt that a 
decrease in cholesterol will decrease the incidence of CHD 
(10,11,26,41). In fact, it is noted that for each 1% 
reduction in cholesterol, there is a corresponding 2% 
decrease in CHD mortality (39,48). So of the possible 
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effects of EPA in the Eskimo diet, the one of primary 
significance may be the lowering of total cholesterol. Most 
studies in which the Eskimo diet has been simulated by 
supplementing the normal diet with fish-oils have provided 
evidence that a reduction in total cholesterol occurs (4-
6,44,52). The results are encouraging enough to stimulate 
additional research. 
Decreasing the dietary intake of total fat in addition 
to increasing the amount of polyunsaturated fat are but two 
ways in which the incidence of CHD can be decreased. Weiner 
et al. (60) proposed four ways in which atherosclerosis 
is initiated and perpetuated: (1) monocyte adherence and 
migration; (2) endothelial injury; (3) platelet 
aggregation and the release of platelet secretory products; 
and (4) lipid accumulation. Prostaglandin metabolism may be 
important in many or all of these processes and modifying 
prostaglandin metabolism may influence the development and 
progression of atherosclerosis. It has been proposed that 
platelet membranes rich in EPA alter prostaglandin synthesis 
and metabolism, thereby EPA may indirectly influence the 
development of CHD. 
Weiner et al. (60) found that feeding hyperlipidemic 
swine a diet rich in cod-liver oil (a marine lipid rich in 
EPA) decreased the development of atherosclerotic lesions. 
The proposed reason for this finding was in the decrease of 
platelet arachidonic acid and increase of platelet 
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eicosapentanoic acid thereby altering the prostaglandin 
metabolism. Through this process, platelet aggregation was 
decreased as well as lipid accumulation, and therefore 
decreases in atherosclerotic lesions were noted. 
Lee et al. (40) noted that a diet high in 
polyunsaturated fatty acids altered the function of 
monocytes. In the early stages of hypercholesterolemia, 
monocytes adhere to the atrial endothelium then migrate to 
the intima. They are then transformed in macrophages, 
acting not only as lipoprotein and cholesterol lesion 
scavengers, but also they may release certain chemicals 
which are growth factors stimulating the proliferation of 
arterial smooth muscle (40). Monocytes containing increased 
amounts of EPA may decrease the amount of leukotriene B4 
produced. Leukotrienes are the product of arachidonic acid 
via the 5-lipooxygenase pathway. Leukotriene B4 has been 
shown to aid in the adhesion of monocytes to the vessel 
walls, therefore, as EPA increases within the cell membrane 
less leukotriene B4 is produced and monocytes are less 
adhesive (40). 
Although most research studies have found EPA to be 
beneficial in raising platelet EPA, decreasing cholesterol 
and triglyceride levels and increasing HDL cholesterol, some 
authors have not found this to be true (27,49). This 
finding however appears to be related to at least four 
reasons: (1) the dosage of EPA administered; (2) the 
duration of therapy; (3) the population sampled; and 
finally, (4) the type of placebo administered. 
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Sanders et al. (50) found no change in total 
cholesterol in 10 healthy subjects, however, the duration of 
administration was only two weeks and the placebo used was a 
mixture of 10 g./day of olive oil and vegetable oil. 
Both olive oil, a monosaturated fatty acid, and vegetable 
oil, a polyunsaturated fatty acid have been found to 
decrease plasma cholesterol and triglyceride levels (28,30). 
Therefore, it is possible that there was not a significant 
difference in the treatment and control groups lipid levels 
because the control group placebo also lowered lipid levels. 
Green et al. (27) found no change in total cholesterol, 
HDL cholesterol, or bleeding time in 11 stroke patients 
after having administered 10 capsules of MaxEPA (1.8 grams 
EPA daily) for a period of six weeks. Again the major 
constituent of the placebo was olive oil. It is possible 
that the mechanism for cholesterol synthesis and metabolism 
in patients with documented cardiovascular disease may be 
different from that of healthy subjects. It is known that 
hypercholesterolemia is a familial disease process and 
exists as a result of a heterozygous or homozygous gene 
(53). The heterozygous type is the least severe, however 
each type exhibits distinct clinical manifestations, the 
most severe of which is the early development of 
cardiovascular disease. 
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F~milial hypercholesterolemia (FH) has been classified 
according to different phenotypes: Type I (excessive 
chylomicrons); Type IIa (increased LDL with normal VLDL); 
Type IIb (increased LDL and VLDL); Type III (increased 
intermediate lipoproteins); Type IV (increased VLDL); and 
Type V (increased VLDL and chylomicrons). 
Phillipson et al. (46) administered three different 
diets to 10 subjects"with Type IIb (mean total cholesterol 
(TC) 337 mg./dl. and mean triglycerides 335 mg./dl.) and 10 
subjects with Type V (mean TC 514 mg./dl. and mean 
triglycerides 2874 mg./dl. ). The diets consisted of a 
control diet (typical low-fat, polyunsaturated to saturated 
fat ratio [P:S] of 1:4), a diet high in fish-oil (20-30% 
kcal. from fish-oil), and a vegetable oil diet (20-30% kcal. 
from vegetable oil). The Type IIb group had reductions in 
both plasma cholesterol and triglyceride levels of 27% and 
64% respectively when fed the fish-oil diet. The Type V 
group had even greater decreases of 45% and 79% 
respectively. The vegetable oil diet produced decreases in 
the lipid levels, however they were not as significant (46). 
Because of the differences between these groups it has 
been hypothesized that the mechanism for lipid metabolism is 
different for different types of familial 
hypercholesterolemia. Cuthbert et al. (14) attempted to 
test for these effects by administering the drug mevinolin 
to subjects with different phenotypes. Mevinolin disrupts 
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the synthesis of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-
CoA), the necessary enzyme in LDL metabolism. It was found 
that those subjects with the heterozygous form of FH could 
benefit most from the administration of mevinolin. Thus the 
theory that different phenotypes respond at different levels 
to treatment was borne out. 
The dosage of EPA required to produce the desired 
effects, as well as the duration of administration, has been 
a point of controversy. The true Eskimo diet contained a 
daily amount of 7 grams of omega-3 fatty acids.* In the 
various investigations, as much as 10 g./day (36) and as 
little as 1.1 g./day have been used (53). Similarly broad 
limits to the length of administration have been used, as 
little as 2 weeks on the one hand (50), and as much as 2 
years on the other (47). Peak effectiveness appears to lie 
in dosage levels of 2.9 g./day and above and in treatment 
intervals of a minimum of three weeks. However, in those 
studies in which there was a decrease in lipid levels 
following administration of EPA, lipid levels returned 
to pre-treatment levels soon after administration was 
discontinued. 
It is evident that additional research is needed with 
respect to the choice of controls, the population effects, 
* Taken from the Sept. 26, 1985 issue of 1h~ Ne~ 
EnglanQ JQurngl Qf Medicine, Letters to the Editor, pp.823. 
dosage levels, and length of therapy employed in the 
administration of EPA. 
Lipids and Lipid Metabolism 
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In order to fully understand cholesterol, its 
importance to the body, and how it could be altered by the 
administration of dietary fish-oil, it is necessary to have 
an understanding of lipids in general, and the chemical 
reactions taking place. 
Cholesterol 
Cholesterol is a principal member of a class of organic 
compounds known as steroids, however it is often classified 
as a lipid because of its insolubility in water (55). 
Cholesterol is present in all animal tissue and is 
synthesized primarily in the liver and intestine (8). If 
synthesized within the body it is described as endogenous, 
and exogenous if it is ingested as part of the diet. The 
rate of total cholesterol absorbed by the body is 
approximately 1 gram per 24 hour period. Of that the 
exogenous cholesterol intake averages approximately 600 
mg. per day, 300 mg. of which is the maximum which can be 
absorbed. Approximately 1 gram of sterol is excreted daily 
in the feces. The net result is that an approximate steady 
state for cholesterol exists in the healthy body (54). 
Cholesterol is essential to the body for vitamin D 
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synthesis, hormone production, cell membrane formation, and 
it is the precurser to cholic acid produced as bile salts 
which aid in digestion (54,8). Cholesterol is so vital to 
cellular function that cells will retain cholesterol at the 
expense of other needed compounds. 
Lipids 
In broad terms the word lipid is used to describe a 
variety of biologically important molecules which are water 
insoluble. Included in these groups are the triglycerides, 
phospholipids, steroid and steroid esters, glycolipids, and 
lipoproteins (54). Fatty acids form the skeleton of the 
lipid molecule. They generally consist of an even number of 
carbon atoms with a carboxylic acid group at one end. Often 
the acid group has reacted with an alcohol to form an ester. 
These fatty acids may be saturated, monosaturated or 
polyunsaturated. If saturated, all the carbon-carbon bonds 
are single. If monosaturated, one carbon-carbon double bond 
is present, and if polyunsaturated, two or more double bonds 
are present. The majority of the cholesterol in the body is 
esterified by reacting with a fatty acid, e.g., linoleic 
acid to give cholesteryl linoleate (8,54,55). 
Fatty Acids 
Fatty acids are used by the body for energy production 
(oxidation) and for energy-consuming processes (reduction). 
Fatty acids are available in the liver where they originate 
from synthetic processes involving excess dietary 
triglyceride, hydrolysis of chylomicron triglycerides, and 
through the mobilization of fatty acids from adipose tissue 
(54). 
Some fatty acids are known as essential fatty acids 
because they can not be manufactured by the body and are 
required in some way for the metabolism of cholesterol and 
other lipids. Without them abnormal accumulations of 
cholesterol and triglycerides form in the liver. Essential 
fatty acids are also the precursers to the prostaglandins. 
Among the most important of these are linoleic acid and 
arachidonic acid. Linoleic is the most abundant of the 
fatty acids that combine with cholesterol to form 
cholesteryl esters. Fatty acids are classified according to 
the number of carbon atoms in their chain (8,54). 
Triglycerides 
Triglycerides (true fats) are formed by combining three 
fatty acid molecules (usually different from one another) 
with a single glycerol molecule to form a tri-ester. 
Triglycerides are identified by the fatty acid component. 
The shorter the fatty acid chain, the lower the melting 
point of the fat. Triglycerides are the principle lipids of 
foodstuffs, as well as adipose tissue. They are well suited 
in the role of energy production as 9 kcal of energy is 
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yielded per gram of fat. ln addition, these fats are non-
polar and can be stored efficiently within a cell (8,54). 
Phos2holi2ids 
Contained within the phospholipid molecule is glycerol, 
two fatty acids (one saturated) which form carboxylate 
esters, one phosphate ester and a nitrogen base. 
Phospholipids are present in food and in tissue and act as 
emulsifying agents which help digest food by breaking down 
fats (emulsifying) into colloidal particles for easier 
transport. Because triglycerides are water insoluble and 
the enzymes needed for these reactions are water soluble, 
the triglycerides must first be finely dispersed 
(emulsified) with the aid of phospholipids for more intimate 
mixing before the metabolic reactions can occur (54). 
Lipoproteins 
Lipoproteins are long chain fatty acids with a protein 
molecule attached. Lipoproteins are classified as 
chylomicrons (the largest and lightest), very low density 
lipoprotein (VLDL), low density lipoprotein (LDL), and high 
density lipoprotein (HDL). They are critical to the 
transport process for insoluble materials in a subtle three-
tier system. The water soluble proteins bond with the water 
insoluble lipid to form lipoproteins. Then the cholesterol 
and other lipids associate with this complex to be 
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transported to the cells where they are needed (54). 
Chylomicrons 
The chylomicrons contain 80 to 95% exogenous 
triglyceride, 2 to 7% cholesterol, 3 to 6% phospholipid and 
1 to 2% protein. These molecules are synthesized in the 
intestine and carry most of the dietary cholesterol to the 
plasma where the fatty acids and glycerols are broken away 
and either used or stored by the cells. The remnants are 
cleared by the liver (54). 
VLDL contains 60-80% glyceride and carry endogenous 
(synthesized primarily in the liver) triglycerides. These 
triglycerides are transported from the liver to muscle and 
adipose tissue where it is either used or stored (54). 
LDL originates at least partially from the VLDL. It is 
composed of about 50 to 75% cholesterol and 25% protein. 
The LDL remnants are very slowly removed from the liver (2-5 
days), and because of the high concentration of cholesterol 
are thought to have the grea~est athrogenic potential (54). 
HDL contains about 50% protein, 30% phospholipid and 
20% cholesterol and is the smallest of the lipoproteins. 
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The exact function of HDL is not known, however, because it 
is composed of greater amounts of protein and phospholipids 
than cholesterol it is often termed "good" cholesterol (54). 
Some researchers also claim that HDL circulates in the blood 
stream acting as a "scavenger" for excess cholesterol 
remnants adhering to the arterial walls and carrying them 
back to the liver where they can be metabolized, formed into 
bile salts, or excreted in the feces (11,13). 
This completes the discussion of the lipids and the 
particular interactions between them and cholesterol. If 
one focuses on the role of LDL as the principle culprit in 
the athrogenic process, one learns that considerable 
information is known about its function. 
The LDL Receptor 
Goldstein and Brown won the Nobel Prize in 1985 for 
their work with LDL and LDL receptors (9). The LDL 
receptors remove cholesterol from the vascular system by a 
process known as receptor mediated endocytosis. There are 
two types of lipoprotein receptors: (1) LDL receptors, 
those that bind the lipoproteins carrying endogenous 
cholesterol derived from non-intestinal sources; and (2) 
chylomicron remnant receptors, those that bind lipoproteins 
containing exogenous cholesterol absorbed from the 
intestines. 
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LDL receptors are extremely important to cell 
metabolism and are present on the surface of all mammalian 
cells. They provide the cells with needed cholesterol for 
growth by mediating the uptake of plasma LDL. Most of the 
receptors are located in the liver where they are needed to 
supply cholesterol for bile secretion, for conversion to 
bile acids, and for resecretion into the blood stream to be 
transported by newly formed lipoproteins (9). 
Located on the cell membrane are so-called "coated 
pits" that have the responsibility for regulating a number 
of receptor-bound molecules in the process of receptor-
mediated endocytosis. The LDL binds to the receptor by 
attaching to a protein in the coated pit, then within a few 
minutes the pit invaginates into the cytoplasm releasing its 
cholesterol into the cell (9). 
The process, like many life processes, is controlled 
enzymatically. There appear to be three mechanisms which 
control cholesterol levels in the cell. First, if the 
enzyme (HMG-CoA) is suppressed, the cell will preferentially 
use exogenous cholesterol derived from the receptor mediated 
uptake of LDL. However, if this too is not available, it 
will stimulate the cell to produce its own cholesterol. 
Secondly, an excess of endogenous cholesterol activates an 
enzyme that re-attaches a fatty acid to the excess 
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cholesterol to form an ester that can be stored in droplets 
in the cytoplasm. The third cholesterol regulating 
mechanism by the cells is called a "feedback" system and is 
perhaps the most important. Excess cholesterol inside the 
cell causes it to shut off the synthesis of any new 
receptors so that new cholesterol can not be taken into the 
cell. Through this mechanism the cell is able to regulate 
the intake of cholesterol. When cholesterol is needed, such 
as in times of growth, it can be taken in by some 40,000 
receptors per cell. Then, when growth ceases, the receptor 
sites can be shut down to approximately 36,000. The 
discovery of the LDL receptor shed new light on familial 
hypercholesterolemia and the treatment thereof (9). 
Although fats have many useful functions within cells, 
there are detrimental aspects of fats to be considered and 
these should be remembered when considering the beneficial 
effects purported to occur for EPA. An increased intake of 
saturated fats has been shown to increase serum cholesterol 
levels (54). Although the mechanism for this is not well 
understood, two theories have been proposed. It is possible 
that an increased consumption of saturated fatty acids 
decreases bile acid secretions resulting in less efficient 
metabolism of cholesterol and an increase in the build up of 
the sterol. Secondly, it has been proposed that increasing 
the ratio of polyunsaturated to saturated fatty acids in the 
diet transfers the amount of cholesterol from the vascular 
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system to the muscular tissues of the body (54). In 
addition, it is the hypothesis of this author that because 
the lipoprotein carriers are at least partially composed of 
lipids, as dietary intake of fats increases more of the 
lipoprotein carriers are occupied resulting in more 
cholesterol, triglycerides, and phospholipids being 
circulated throughout the body. It is also conceivable that 
more of the LDL receptors on the cells are engaged. 
In reviewing the literature regarding the effects of 
the oral administration of fish-oil, it is the purpose of 
this work to conduct a study in which the dosage level, 
duration of therapy and population type are optimized in a 
controlled double blind study. 
CHAPTER III 
METHODS AND PROCEDURES 
This study investigated the effects of MaxEPA (tm), a 
commercially prepared fish-oil (supplied by the R. P. 
Shearer Co., and Dr. Desmond Davies), on total cholesterol 
(TC), high density lipoprotein cholesterol (HDL/C), and 
bleeding time (BT). The methods and procedures were 
submitted to and approved by the Oklahoma State University, 
Institutional Review Board. 
A total of eleven subjects participated in this cross 
over design study which lasted 6 weeks. The subjects were 
required to orally ingest 10 capsules daily of either MaxEPA 
(tm) or an olive oil placebo for the duration of the study. 
Blood samples were taken at the beginning, at cross over, 
and at the conclusion of the study. Standardized clinical 
methods were used for analyses. 
Selection of Subjects 
The 11 subjects in this study, 9 males and 2 females, 
were volunteers chosen from a group of subjects that had 
participated in the Cardiac Rehabilitation Program at the 
Oklahoma State University Health and Fitness Center. The 
subjects had documented CHD in the form of atherosclerotic 
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heart disease. The ages of the subjects ranged from 40 to 
71 years (mean 58.5). In order to be selected for the study 
an individual's total cholesterol had to exceed 240 mg./dl, 
or the total cholesterol to high density lipoprotein ratio 
(TC/HDL) had to exceed 5:1, or both. Medical approval for 
the selection and permission to participate in the study 
were obtained for each subject by way of a telephone 
conversation with their personal physician before the 
program began. 
The subjects were randomly assigned to one of two 
groups. Group I began the study by taking the placebo then 
crossed over to the treatment. Group II began by taking the 
treatment then crossed to the placebo. 
Personal Data 
Upon arrival at the Cardiac Rehabilitation laboratory, 
each subject was asked to fill out a brief health history 
(see Appendix A) which was updated from the personal history 
already on file since these subjects had been involved in 
the rehabilitation program in the past. Included on the 
form were questions regarding name, age, sex, address, 
telephone number, smoking history, alcohol consumption 
history, exercise history, family history of heart disease, 
personal history of heart disease, lipid levels, and current 
medications (see Appendix A). 
Additionally, each subject was required to read and 
sign an informed consent for the testing procedure and a 
disclaimer for bleeding disorders. The forms were 
thoroughly explained to the group by the investigator and 
questions were answered to the satisfaction of each of the 
subjects (see Appendix A). 
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All subjects were requested to write down on a diet 
diary (see Appendix A) the exact amounts and types of foods 
consumed on two week days and one weekend day and return it 
to the laboratory upon completion. 
All the procedures were then carefully explained to the 
subjects, instructions given regarding how the capsules 
should be taken, what time of day they should be taken, and 
when the subjects should return for the next series of 
tests. The subjects were also reminded that normal exercise 
and diet regimens should not be altered while participating 
in the- study. 
For each of the test periods that followed, this same 
protocol was used. 
Testing Procedures 
All subjects reported to the Cardiac Rehabilitation 
laboratory having fasted for at least 12 hours previous to 
their arrival (they were instructed that they could drink 
only water, see Appendix A). Personal histories were 
collected, the proper forms completed (see Appendix A), and 
height and weight were measured and recorded. 
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At the outset, total cholesterol (TC), high density 
lipoprotein-cholesterol (HDL/C), and bleeding time (BT) were 
obtained on two consecutive days to determine a steady 
baseline for each. After the second day, the subjects were 
randomly assigned to one of two groups. One group of 
subjects was given a 21 day supply of an inert placebo and 
the other group the MaxEPA (tm) capsules. All of the 
capsules were bottled in the same manner and neither the 
. 
investigator nor the subjects knew which treatment they were 
receiving, yielding a double blind design. The subjects 
were instructed to take by mouth, 10 MaxEPA (tm) capsules 
daily (1.8 g. EPA) for the prescribed period. The subjects 
were thoroughly briefed in regard to the protocol of the 
study and instructed to return on the proper date. 
In 21 days the subjects returned to the Cardiac 
Rehabilitation laboratory, again having fasted for at least 
12 hours. The same measurements (TC, HDL/C, BT) were 
obtained and recorded on two consecutive days. Weights were 
also measured and recorded to insure dietary compliance. 
After the second day of laboratory testing the subjects were 
given another 21 day supply of capsules. The placebo group 
was given the MaxEPA and the MaxEPA group was given the 
placebo. The subjects were again reminded of the proper 
protocol and instructed on when to return for final testing. 
In another 21 days (42 days after initial screening) 
the subjects arrived back at the laboratory for the final 
series of testing, again in a fasting state. The blood 
samples for TC, HDL/C, and BT were again obtained on two 
consecutive days, and body weights were measured and 
recorded. Another 3 day dietary recall was completed by 
each subject to further insure compliance to dietary 
instructions. 
Clinical Laboratory Procedures 
Total Cholesterol ~ HDL/Cholesterol 
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In order to determine the total cholesterol (TC) and 
HDL/Cholesterol (HDL/C) levels in the blood a venous blood 
sample was drawn from the brachial fossa of either the right 
or left arm of each of the subjects. Standard aseptic 
venipuncture technique was employed with the tourniquet 
being released prior to removal of the #21 gauge needle. 
All subjects were in the sitting position during 
venipuncture. Vacutainer (tm) red stoppered tubes (serum 
separation tubes, SST) were used in venous collection. 
These have a floating gel to aid in separation of the red 
cells from the serum. One tube per subject was collected 
(approximately 10 ml.). 
All venous samples were allowed to stand at room 
temperature for a minimum of 30 minutes and a maximum of 1 
hour 30 minutes until a clot was formed in the tube. The 
samples were then centrifuged at a speed of 5,000 
revolutions per minute for five minutes in a table top 
clinical centrifuge (International Equipment Co., model 
#428-17108, Needham, Ma.). The gel then separated the red 
cells from the serum. The supernatant serum was aspirated 
using a disposable transfer pipette and pinch bulb and 
transferred into a new glass test tube and stoppered. At 
this point the serum was ready to be analyzed. 
Total cholesterol was analyzed in the Vision (tm) 
automated blood analyzer by placing two drops of each 
subject's serum into the Abbott Laboratories "cholesterol 
kits" (furnished by the Oklahoma State University, Health 
and Fitness Center) (3). 
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HDL cholesterol was analyzed using a manual separation 
technique in which magnesium phosphotungstate is added to 
precipitate low density lipid fractions (3). The HDL in the 
resultant supernate was analyzed in the same manner as 
described for cholesterol. 
Both TC and HDL/C samples were analyzed within 4 hours 
of being collected. Prior to each set of measurements the 
Vision (tm) blood analyzer was calibrated with Abbott 
controls. 
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Bleeding Time 
Bleeding time was determined using Duke's Method (59). 
A uniform puncture depth of 3 m.m. was accomplished by using 
the Autolet (tm) lancet. Bleeding time was measured in 30 
second time intervals by blotting the puncture with a piece 
of filter paper. The wound was allowed to clot with no 
pressure being exerted on it. The same finger and the same 
site was used in each of the test periods to insure 
uniformity. 
Apparatus and Equipment 
The essential pieces of equipment used in this study 
were the Vision (tm) automated blood analyzer (Abbott 
Laboratories, Dept. 99F, North Chicago, Il., 60064), Abbott 
Laboratories dry chemistry cholesterol kits, the Autolet 
(tm) lancet, and the clinical centrifuge (International 
Equipment Co., 300 Second Ave, Needham Hts., Mass.) 
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Statistical Treatment 
This study was placebo controlled, double blind, and 
employed a cross-over research design. In this design each 
subject was allowed to act as his own control (12,43). 
The data were analyzed using the 2 x 2 repeated 
measures analysis of variance with a grouping factor at two 
levels (group 1 vs. group 2), and a trial factor at two 
levels (period 1 vs. period 2). The following dependent 
variables were each analyzed separately: (1) total 
cholesterol; (2) high density lipoprotein cholesterol; and 
(3) bleeding time. All statistical tests were performed 
using the .05 level of significance. Statistical analysis 
was done through the Oklahoma State University Computer 
Center. 
CHAPTER IV 
RESULTS AND DISCUSSION 
The purpose of this study was to determine if MaxEPA 
had a beneficial effect on total cholesterol, high density 
lipoprotein cholesterol, and bleeding time in 11 patients 
with a documented history of coronary heart disease. The 
experimental design was a double blind cross-over utilizing 
two groups with each subject acting as their own control. 
Groups were controlled by administering a placebo. 
Of the 11 subjects (9 male and 2 female), all had 
documented histories of CHD in varying degrees of severity. 
Eight of the 11 subjects had undergone coronary artery 
bypass graft surgery (CABG), one had had an inferior 
myocardial infarction (MI), and two had undergone balloon 
angioplasty on one or more coronary arteries. Additionally, 
one subject had had an MI, then CABG, then angioplasty and 
one subject had had an MI prior to CABG surgery. All 
subjects were at least 12 weeks and not more than 3 years 
post coronary event. All of the subjects were on prescribed 
low fat diets (below 30%), and all exercised a minimum of 20 
minutes, three times per week. One of the subjects 
continued to smoke cigarettes. Phenotyping histories were 
not available to the investigator. Descriptive information 
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is depicted in Table I. 
All of the subjects that began completed the study. The 
supplement was tolerated well by all subjects, however, 
there were instances in which mild gastric distress was 
noted. 
Results 
Pre test results are given in Table II. Experimental 
data are given in Table III. 
Results Q! Total Cholesterol AnalYsis 
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The results of the total cholesterol analysis by group 
and by period are given in Table IV. There was no change in 
total serum cholesterol levels at the .05 level of 
significance. 
Results of HDL-Cholesterol Analysis 
The results of the HDL/C analysis by group and by 
period are given in Table V. There was no change in high 
density lipoprotein cholesterol levels at the .05 level of 
significance. 
Results Q! Bleeding ~ Analysis 
The results of the bleeding time analysis by group and 
by period are given in Table VI. There was no change in 
bleeding time at the .05 level of significance. 
TABLE I 
DESCRIPTIVE DATA 
Subject Group Sex Age Weight Percent 
Dietary Fat 
1 1 F 48 108 17.7 
2 2 M 71 153 36.0 
3 . 2 M 52 183 30.7 
4 1 M 50 169 21.7 
5 2 M 71 172 31.7 
6 2 M 64 208 35.7 
7 1 M 59 189 28.3 
8 1 F 61 156 32.7 
9 1 M 40 184 44.7 
10 2 M 68 146 13.3 
11 2 M 59 184 16.3 
-X 58.5 168.4 28.1 
SD 10.0 26.9 9.7 
CABG= Coronary artery bypass graft surgery 
MI= Myocardial infarction 
Angio= Coronary artery balloon angioplasty 
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History of 
CVD 
CABG 
MI, CABG 
CABG 
ANGlO 
CABG 
CABG 
CABG 
MI 
MI, CABG 
ANGIO 
CABG 
ANGlO 
4'7 
TABLE II 
PRE TEST DATA 
GROUP l 
Starting Points 
Subject Age Sex T.C. HDL/C B.T. 
(mg. /dl.) (mg. /dl. ) ~min. ) 
1 48 F 321.9 36.2 3.0 
4 50 M 236.9 37.3 5.0 
7 59 M 266.5 28.0 4.5 
8 61 F 266.4 44.3 3.5 
9 40 M 198.5 34.0 4.5 
-X 51.6 258.0 36.0 4.1 
SD 8.6 45.3 5.9 0.8 
GROUP ll 
Starting Points 
Subject Age Sex T.C. HDL/C B.T. 
(mg. /dl. ) (mg. /dl. ) l min. ) 
2 71 M 232.5 40.8 4.0 
3 52 M 236.9 38.4 3.0 
5 71 M 245.8 50.2 1.5 
6 64 M 237.8 38.9 3.0 
10 68 M 202.3 39.5 6.0 
11 59 M 304.9 36.8 7.5 
X 64.2 243.4 40.8 4.2 
SD 7.5 33.7 4.8 2.2 
T.C.= total cholesterol 
HDL/C= high density lipoprotein cholesterol 
B.T.= bleeding time 
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TABLE III 
EXPERIMENTAL DATA 
~RQUP l 
Treatment Placebo 
Subject T.C. HDL/C B.T. T.C. HDL/C B.T. 
(mgjdl) (mgjdl) (min) (mg/dl) (mg/dl) (min) 
1 340.5 47.0 7.0 306.8 46.1 4.75 
4 204.1 38.8 5.5 225.5 32.7 6.75 
7 264.0 33.2 5.0 276.6 35.0 4.25 
8 235.5 50.3 3.5 231.0 30.2 4.5 
9 215.3 36.6 3.5 198.8 35.0 5.75 
-
X 251.9 41.2 4.9 247.7 35.8 6.1 
SD 54.5 20.0 1.5 43.3 6.1 1.0 
~ROUP ll 
Treatment Placebo 
Subject T.C. HDL/C B.T. T.C. HDL/C B.T. 
(mg/dl) (mg/dl) (min) (mg/dl) (mg/dl) (min) 
2 246.2 45.5 5.5 231.0 48.0 4.0 
3 224.8 39.7 3.75 218.6 43.4 4.0 
5 264.6 60.6 3.5 245.4 59.4 2.75 
6 220.4 33.9 6.5 211.3 40.0 8.5 
10 211.6 47.9 8.25 194.5 45.7 9 h ..... 
11 324.5 45.5 4.75 265.2 41.1 4.25 
-
X 248.8 45.5 5.4 227.7 46.3 5.5 
SD 41.8 9.0 1.8 25.2 7.1 2.8 
Group I began the study ingesting the placebo, Group II 
began by ingesting the MaxEPA (tm) capsules. 
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TABLE IV 
ANALYSIS OF VARIANCE FOR 
TOTAL CHOLESTEROL 
--·--·-----·----
SOURCE ss d. f. M.S. F* 
--~---
Group 736.39 1 736.39 0.23 
Error a 29406.12 9 3267.35 
Period 505.44 1 505.44 2.38 
Group X Period 863.56 1 863.56 4.06 
Error b 1913.10 9 242.57 
Total 33424.61 21 
*Critical Value for Fat .05 level of significance= 5.12 
SOURCE 
Group 
Error a 
Period 
TABLE V 
ANALYSIS OF VARIANCE FOR HIGH DENSITY 
LIPOPROTEIN CHOLESTEROL 
ss d. f. M.S. 
208.29 1 298.29 
818.81 9 90.98 
45.10 1 45.10 
Group X Period 29.02 1 29.02 
Error b 192.36 9 21.37 
Total 1293.58 21 
*Critical Value for F at .05 level of significance 
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B,-+ 
3.28 
2.11 
1. 36 
= 5.12 
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TABLE VI 
ANALYSIS OF VARIANCE 
FOR BLEEDING TIME 
SOURCE ss d. f. M.S. F* 
Group 0.82 1 0.82 0.13 
Error a 57.02 9 6.34 
Period 0.03 1 0.03 0.02 
Group X Period 0.25 1 0.25 0.21 
Error b 10.70 9 1.19 
Total 68.82 21 
*Critical Value for Fat .05 level of significance= 5.12 
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Discussion of Results 
The interaction between eicosapentanoic acid (EPA, the 
major constituent of MaxEPA) and the blood platelets is not 
at present clearly understood. There are conflicting 
results in the literature as to whether EPA is in fact a 
beneficial treatment for hyperlipidemia. Clearly, in this 
study, using this population, at this dosage level, and 
using an olive oil placebo for a 3 week period, no 
beneficial outcome was derived. 
Although the reasons for this outcome can not be 
explained totally because the mechanism of action can not be 
explained, there are several possible interpretations. One 
primary area of concern which has been noted in recent 
literature is the reliability of automated blood analyzer 
results (7,56). Superko et al. (56), reported that of 130 
clinical laboratories that participated in a study to test 
the accuracy of HDL/C results, 52% varied from the overall 
mean by more than 7.5%. In clinical numbers this variation 
represents approximately 34.5 mg./dl. In another 40% of the 
laboratories surveyed the results varied about the mean by 
greater than 10%. 
The January 1988 issue of Clinical Chemist~ reported 
that the Center for Disease Control surveyed 5,000 
laboratories to analyze the accuracy of total cholesterol 
testing (7). The results revealed that 47% of those labs 
surveyed were greater than plus or minus 5% of the control 
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value. The control value was a "true value" traceable to 
the Center for Disease Control and the National Bureau of 
Standards. Additionally 16% of the 47% were greater than 
plus or minus 10% of the control value (7). Although daily 
controls for the Vision (tm) blood analyzer that were run 
prior to each test period were acceptable, there is still a 
possibility of deviation in both the total cholesterol and 
HDL/cholesterol values. 
In the Abbott dry chemistry kits which were used in the 
analysis of both TC and HDL/C, a red color is produced when 
reacted with cholesterol in human serum. The color 
intensity is determined from the amount of light absorbed 
from an internal light source within the Vision (tm) 
machine. Because the color produced is red there is the 
possibility that the color could be enhanced by such 
interfering substances as hemolyzed blood cells. Although 
the machine does have an internal safeguard to print an 
error message if such an event occurs (3), slight changes in 
color are not sufficient to activate the error message. The 
resultant TC or HDL/C level could be affected by these 
subtle changes in the red color. In addition, the light 
source used within the Vision (tm) blood analyzer is 
filtered to produce a single wavelength at 500 n.m., which 
is where the red color absorbs. Measurement at a single 
wavelength light source is minimal at best. A more accurate 
method would be to read the sample using several different 
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wavelengths and then average the readings to determine the 
TC and HDL/C levels. This problem is not confined to the 
Vision (tm) blood analyzer, but is a problem for all 
clinical laboratories in which a single wavelength is used. 
Among the other factors which have recently been cited 
as having an effect on cholesterol readings are: (1) body 
position; (2) time of year; (3) coffee consumption; and t4) 
how long the tourniquet is on the arm before removing the 
sample (56). It is certainly difficult, if not impossible 
to control these variables even for an individual subject 
which evidently produces unreliabilities in TC and HDL/C 
levels. 
The majority of the literature in which a statistical 
decrease in TC and HDL/C has been shown from the 
administration of fish-oil, has been for healthy populations 
(37,40,46). In the study by Green et al. (27), in which 1.8 
gm. EPA was administered daily for 6 weeks in stroke 
patients, no significant decrease in TC, HDL/C, or bleeding 
time was found. This leads one to suspect that perhaps 
there is a genetic deficiency in those with atherosclerotic 
diseases that perhaps somehow affects the action of EPA. 
Although the LDL receptor-mediated endocytosis theory 
appears to be well documented in healthy individuals (9), 
there is much needed research still to be done regarding the 
atherosclerotic patient and the LDL receptor. 
Bleeding time was measured in this study using Duke's 
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method (59) in which the subject's finger is pricked with a 
small lancet to a uniform depth, and the time is measured 
until bleeding ceases. Although this method is widely 
accepted, an alternative that may have produced more 
reliable results would have been to use Ivy's method (59) in 
which the forearm is pricked instead of the finger. The 
forearm is generally less calloused than the fingers, 
therefore the blood supply is closer to the surface yielding 
results that are more reproducible from subject to subject. 
Other factors that possibly affected the results for 
the present study, were: (1) choice of placebo; (2) length 
of therapy; and (3) dosage level. The placebo used in 
this case was one of an olive oil base. Recent literature 
has shown that diets rich in monosaturated fats 
(particularly olive oil) may have an effect on lowering 
serum cholesterol levels (28). If this is true, the 
administration of an olive oil placebo may effect the 
cholesterol level as much or more than the MaxEPA (tm) 
treatment. It was the intent of this study to gain insight 
as to whether 1.8 gm. of EPA (10 MaxEPA,tm, capsules) given 
daily would sufficiently alter blood lipid levels enough 
that they could be recommended to CVD patients. It is now 
known that MaxEPA (tm) given in this dose for a three week 
period is not sufficient to produce the desired results in 
subjects with documented CVD. 
Finally, the results for the present study might well 
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have been changed by using a larger sample. Because of the 
nature of this study, i.e. attempting to make inference to 
patients with some form of cardiovascular disease, it was 
difficult to solicit volunteers that met the required 
criteria. The cost of a larger study was also prohibitive. 
CHAPTER V 
CONCLUSIONS AND RECOMMENDATIONS 
In recent years the public has been inundated with 
information about elevated cholesterol as a risk factor for 
developing heart disease. As public awareness has risen, 
increasing pressure has been put on physicians and 
pharmaceutical companies to produce a low cost, effective 
means by which cholesterol levels can be lowered without the 
public having to make drastic dietary changes. Because of 
the early studies involving Greenlandic Eskimos, fish-oil 
appeared to possess properties that would actually allow an 
individual to reduce serum cholesterol and still enjoy a 
high fat, high protein diet. Consequently, the market-place 
became flooded with fish-oil supplements that could be 
bought over the counter making claims that cholesterol 
levels could be significantly reduced. 
With this in mind, it was the question of this 
investigator that if fish-oil supplements did in fact lower 
serum cholesterol levels in a healthy population 
could it also lower cholesterol levels in individuals with 
coronary heart disease. 
Therefore, the purpose of this study was to determine 
if the oral ingestion of 10 MaxEPA capsules daily for a 
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period of three weeks would have the desired effect of 
decreasing total cholesterol, increasing high density 
lipoprotein cholesterol, and increasing bleeding time in 
subjects with documented histories of CHD. 
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This study was conducted as a double-blind cross over, 
using a 2 x 2 repeated measures analysis of variance with a 
grouping factor at two levels (group 1 vs. group 2), and 
a trial factor at two levels (period 1 vs. period 2). 
Conclusions 
Based on the hypothesis stated and the limits of this 
study, the following conclusions were made: 
1. The oral ingestion of 10 MaxEPA (tm, 1.8 gm. EPA) 
capsules daily for a period of 21 days has no significant 
effect on total cholesterol. 
2. The oral ingestion of 10 MaxEPA (tm, 1.8 gm. EPA) 
capsules daily for a period of 21 days has no significant 
effect on the high density lipiprotein-cholesterol. 
3. The oral ingestion of 10 MaxEPA (tm, 1.8 gm. EPA) 
capsules daily for a period of 21 days has no significant 
effect on bleeding time. 
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Recommendations 
Based on the data collected in this study, it is 
evident that additional research is needed to establish the 
exact dosage level of MaxEPA, as well as, the proper 
duration of therapy which is required to produce the desired 
effect of decreasing total cholesterol while increasing HDL 
cholesterol. Additional research is also required to focus 
on what population, if any, fish-oil would benefit. 
When making these investigations it would be beneficial 
to include a large enough sample size so that the random 
error in cholesterol testing would not be a factor. It 
would also be advantageous to analyze multiple samples for 
each individual subject and average the resultant 
cholesterol level so that instrument variation would not be 
a factor. 
In light of new research regarding triglycerides and 
the propensity for development of coronary heart disease 
(11), it would be beneficial for future studies to include a 
full lipid profile, including triglyceride levels, as well 
as, low density lipoprotein-cholesterol, and very low 
density lipoprotein-cholesterol. 
Finally, and ideally, studies conducted in this area 
should be longitudinal in nature, spanning several years, 
with samples being analyzed at different times of the year. 
Then data collected could truly reflect the relationship of 
the development of cardiovascular disease with the routine 
ingestion of fish-oil. 
60 
Additional research is warranted in this area to derive 
possible benefits from the oral administration of fish-oil. 
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MEMO: 
FR01'1: 
RE.: 
J .-m111r y 20, J 997 
lo Cat-diac Rehab f·atients 
r<obin 
FISH OIL STUDY 
w~ will beQin the ~ish oil study this lhursd~y, Janu~ry 
22. If you are inter~sted in particip~ting pl~aLe be at the 
l"b sometime between 7 and B a.m. so tm can dr'i\1•1 lhe ~irst 
sr.ries of blood tests. f'LEASE e"t o•- drinl~ nothinrd Ce::cept 
water) from 7:00p.m. lhP night bPfore. 
The e::peri ment wi 11 bP. as fnll OI-l!>: Tal·:e D vc•nous blood 
s;:.mpl e to test your chol ~slerc..l and UDL, and de· a f i nget-
s1 ick to test -for bleeding lime on both Thuq>day and Ft-iday 
mor·ni ngt>. This wi 11 be done on t .. ,o cor.sec:uti ve dt!t')'!i so that 
wr Ci.'ln find • Gt~bl e baseline. lben you wi 11 hc~gi n on the 
-fish oil or a placebo Cyc~u wc111't l::nc1w which or.e \'tn• artt on). 
Vou will be required to tal~e 10 carnmles each day for three 
,.,eel::s. 1 would 1 i l~e for -,•ou to tal·:e them "11 "at· once in the 
evening. Then on February 16th you ~ill return·to the lab 
betw~en 7 and S:OO a.m. ~or the &amP. series of blood te&ts, 
receive your ne~t round of capsules and aQAin take them the 
~an1u wc.oy you did bP.fore for 3 more weeH>. On Ht~rc-h 9lh you 
will return to the lab for the final series of blood tests. 
The ~~periment will take a lolal of 6 weeks. 
It is my thought according to wh~l I know about •lish 
oil" that taking these caps~les will lower your total 
cholesterol and hopefully increase your HDL. All the results 
will be made availallle to·you "t the conclusion.n~ the stud}'• 
In order· to be eligjble t.o pilrtit:ipal£~ you must hvve a 
chol eslerol of 24(1 mg./dl. or abovP or· an HnL of 2t)X or 
lower. This will bP. determined on the first day of testing. 
Also, if you are on ~ny other cholesterol lowering substance 
you will not be.eligible. · 
The possible risks as~oci ated wi~th tnld ng this food 
supplement are. increased bleeding time, some piin or bruising 
associated .,,ith venipunct"re and finge•rsticl:s, and some 
people may e::per-ience a certain degree of indigt-~lion. 
I hope to hav~ at le.:H•.l 10 people- in tt·ds fir~t study. 
l'hanl=:s ~or your ·help! ! ! 
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HEALTH AND FITNESS CENTER 
Oklahoma State Unlver51ty 
The following Information 15 needed for our record5 1nd In 1sses5lng your current 
health 1nd fitness status. ly providing IS ~ch of this lnformltlon IS possible In 
1dvance, time will be saved during the evaluation. All lnfor~tion provided will be 
held In strict confidence. 
NAME DATE 
ADDRESS: Street City State ZIP __ 
H011E PHONE EMPLOYER 
OCCUPATION BUSINESS ADDRESS PHONE 
AGE LAST BIRTHDAY BIRTH YEAR Does your job require physical activity? 
Do you currently smoke? If so, what? number/day 
If not, have you ever smoked? __ If yes, w.,..h-a-t"'"?--------no-../yrs ___ yrs. quit __ 
Do you ever drink alcoholic beverages? If yes, approx. no.: less than 1/day 
1-2 per day ___ 3 or more per day __ _ 
Do you currently participate in any form of exercise on a regular basis? 
Indicate no. of times/weekly of participation: walking jogging----swim 
golf basketball handball/racquetball tennis otile'r1name) --
If you w~job or swim, please indicate distance and time cover~ch session an_d __ _ 
lpproximate pace ----------------------------------
What is your estimate of your current .edical condition? ex. good fair poor 
What Is your estimate of your current physical fitness? ex.::_ good fair poor---
Circle the number of blood relatives (parents, grandparents, brothers, sisters, that have 
been diagnosed as having some form of heart disease: 
Under 60 years of 1ge: 1 2 3 ~ 5 6 7 8 9 Over 60 years of age: 1 2 3 ~ 5 6 7 8 9 
Have you ever been told that you have any form of heart disease? 
Have you ever been told that you have diabetes? 
Do you have blood relatives with diabetes? ---,-f so, how many? __ 
Do you consider yourself to be overweight? If so, approx. how many lbs.? 
Do you have any medical conditions (other than heart disease or diabetes) that might 
affect your exercise performance? ____ If so, please list---------------
Who is your family physician? City.,...---------
Address, If known date last medical exam-------
~/ould you 1 ike your stress test records sent to this physician? __ 
If you would prefer to have your records sent to another physician, please list 
name and address ' 
Are you currently taking any kind of medication? __ _ 
If yes, is It non-prescription? If so, name 
If yes, Is it prescription? __ --rfyes, give name-.... i""f----po-=--s-s~ib~lre-------------
Have you ever been told that you had high cholesterol or high triglyceride levels in the 
blood? Cholesterol: yes ___ no Triglyceride: yes ___ no __ _ 
If you know your cholesterol and/or triglyceride levels, please list 
Cholesterol Triglyceride--------
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OKLAHOMA STATE UNIVERSITY 
HEALTH AND FITNESS CENTER 
I"'AXEPA STUDY 
INFORMED CONSENT 
E!Eke~aiiQ~ QE Is~I 
The tests you are about to undergo are a part of a 
research study involving the oral ingestion of a product 
called eicosapentanoic.acid <EPA>. The purpose of this study 
will be to lftonitor. its effects on serum lipid levels and 
bleeding times. EPA could have possible benefits in the 
reduction of serum lipids and in increasing bleeding times in 
some patients. Since these two factors have ·been strongly 
linked to the incidence of atherosclerotic heart disease, it 
is possible that the ingestion of EPA will decrease the risk 
of devel~pjng heart disease. 
It will be required of you to take 2 grams of the 
substance daily for a period of three weeks, and then a 
placebo for a period of three weeks. You will not know at 
which time you are taking which substance. At the beginning 
of the series of tests it will be required that we take two 
blood samples two days apart to establish a baseline-serum 
cholesterol level. At the end of the first three week 
treatment period aoother blood sample will be drawn, and at 
the end of the second three weel: period. 
Only t~ained personnel will be involved tn the 
e>:traction of blood from the vein at the bend of the arm. In 
addition, a registered nurse will be in attendance during all 
procedures. The traditional venipuncture method will be 
employed. 
Bleeding time will be determined using a small finger 
prick. Again, only trained personnel will be administering 
the treatment. 
Further information regarding any procedures or 
complications can b~ obtained from the Health and Fitness 
Center. The numbers to call if you have questions or suffer 
from a medical problem are: 624-7SS6 <days>, or 377-~283 
<nights>. 
EQaa!!!bs fHa~a 
The potential risks that have been associated with 
Ha~Epa are as follows: (1) increased bleeding time or 
decreased coagulation time; this could cause y6u_to bruise 
more easily or to bleed easily. <2> Alteration of serum 
lipids; this should cause no untoward effects. <3> Decreased 
red blood count; this should not be sufficient to cause 
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anemia. Although the above risks are potentially dangerous, 
Ma~Ep~ in the dosage recommended should not cause harm. 
The potential risks associated with venipuncture are: 
(1) Venipuncture.may cause some pain or discomfort. The 
e~act amount, if ~ny, will be dependent upon individual 
preconceptions and pain threshold levels. C2> Possible 
hematoma (bruising> at the venipuncture site following the 
procedure. The occurrence or non-occurrence will be 
dependent upon bleeding/coagulation times and adherence to 
instructions pertaining to holding a cotton ball against the 
venipuncture site, with pressure, for five minutes following 
e~traction of the needle. (3) Slight risk of infection. Any 
break in the integrity of the skin is associated with a small 
degree of risk of infection. However, if directions are 
followed .t~e risk is very little. 
~Q~§g~r @Y §~@~g~r 
The information which is obtained will be treated as 
privileged and confidential and will not be released or 
revealed to anyone without your express written consent. 
Information will be used for research purposes only as a part 
of group data. Results will be given to you following the 
completion of the study. 
I have read the foregoing, I understand it and any 
questions which may have occurred to me have been answered to 
my satisfaction. 1 understand 1 may withdraw from and 
discontinue my participation at any time that I feel it 
necessary. 
DATE-------------------------------
SUBJECT----------------------------
WITNESS ______ ~---------------------
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r1AXEPA STUDY 
To my knowledlile, I. do not have ulcers, frequent nose 
bleeds, hemophilia, or any other bleedin'il disorders. lf J 
develop any abnormal bleeding I will contact the Health and 
Fitness Center immediately, and di&continue use of the 
Mcll:epa. 
SIGNED--------------------------
loJ I TNESS ________________________ _ 
DATE----------------------------
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SUBJECT INFORHATON SHEET 
EPA STUDY 
1. Do not change any of your dietary habits during the 
course of this study. 
2. Do not change any of your normal exercise routines during 
the study. 
3. On the day prior to having your blood drawn, do not eat 
or drink anything after midnight the night before. 
4. Do not exercise the morning that you are having your 
blood drawn. (You may exercise after) 
5. Do not take any aspirin or aspirin containing products 
during the study. (Anything containing acetlysalicylic acid) 
6. If you are prone to any bleeding disorders (ulcers, 
Hemophilia, etc.) please advise one of the Health and Fitness 
Center employees. 
7. If you have any medical problems that might be associated 
with the taking of'EPA please call Robin at 624-7556 or Frank 
at 624-6753. 
8. You are to return to the Physiology of Exercise Lab (room 
120, Colvin Center) on: 
at 
for your next set of blood work. 
9. If you can not adhere to the above instructions please 
advise the Health and Fitness Center. 
10. Take all medicatons involved in the study in the evening 
before bedtime. 
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HEALTH AND FITNESS CENTER 
DIET DIARY for Weight. Loss/Control Clinic 
Name Date Day ot Week Tel. ________ Add;;;s ___________ --_--_-_-_--
(Indicate eeperate snacks) 
Ilme you eat.. Hh~ you eat. 
BREAKFAST Hllt~ you eat with. Hlllll. you 
are doing. U~H ~U !eel. 
Food, Description, Amount ____ _ 
Total Breakfast Calories 
LUNCH 
Total Lunch Calories 
DIUNER 
-----------------
Total Dinner Calorie~ 
TOTAL CALORIES FOR DAY 
CALORIES 
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